Fortitude Family Office’s Ventyx Biosciences VTYX Stock Holding History

Fortitude Family Office’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-830	Closed	-$7.5K	–	2082
2025 Q4	$7.5K	Hold	830	–	–	﹤0.01%	673
2025 Q3	$2.58K	Hold	830	–	–	﹤0.01%	1106
2025 Q2	$1.78K	Sell	830 -2,347	-74%	-$3.79K	﹤0.01%	1257
2025 Q1	$3.65K	Hold	3,177	–	–	﹤0.01%	802
2024 Q4	$6.96K	Buy	3,177 +2,659	+513%	+$6.03K	﹤0.01%	744
2024 Q3	$1.13K	Sell	518 -126	-20%	-$290	﹤0.01%	1089
2024 Q2	$1.49K	Sell	644 -692	-52%	-$2.88K	﹤0.01%	836
2024 Q1	$7.35K	Buy	1,336 +1,247	+1,401%	+$5.7K	﹤0.01%	470
2023 Q4	$220	Buy	+89	New	+$845	﹤0.01%	990

Other funds holding VTYX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fortitude Family Office's VTYX Position: Q1 2026 in Review

Fortitude Family Office sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 830 shares — an estimated $7.5K sold.

Fortitude Family Office first reported a position in VTYX in Q4 2023 and held it in 9 quarters. The position peaked at $7.5K in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.

Fortitude Family Office reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
Fortitude Family Office sold 830 Ventyx Biosciences shares in Q1 2026, an estimated $7.5K.
Fortitude Family Office first reported a position in Ventyx Biosciences in Q4 2023 and held it in 9 quarters.
Fortitude Family Office's Ventyx Biosciences position peaked at $7.5K in Q4 2025.
1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.

Based on Fortitude Family Office's 13F filing for Q1 2026, filed 16 Apr 2026.